Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade D 22.48 -5.86% -1.40
NKTR closed down 5.86 percent on Friday, January 17, 2020, on 1.18 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical NKTR trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.86%
Calm After Storm Range Contraction -5.86%
Inside Day Range Contraction -5.86%
Wide Bands Range Expansion -5.86%
Fell Below 200 DMA Bearish -4.30%
Stochastic Sell Signal Bearish -4.30%
Volume Surge Other -4.30%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Chemistry Biotechnology Biopharmaceutical Manufacturing Pharmaceutical Pain Drugs Pharmacology Ovarian Cancer Chronic Pain Morphinans Anti Infectives Metastatic Breast Cancer Opioid Antagonists Pegylation Diols Metastatic Colorectal Cancer Opioid Induced Constipation Treatment Of Metastatic Breast Cancer

Is NKTR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 47.11
52 Week Low 15.635
Average Volume 2,954,388
200-Day Moving Average 25.43
50-Day Moving Average 21.25
20-Day Moving Average 22.62
10-Day Moving Average 23.77
Average True Range 1.62
ADX 18.75
+DI 29.29
-DI 27.09
Chandelier Exit (Long, 3 ATRs ) 23.75
Chandelier Exit (Short, 3 ATRs ) 24.81
Upper Bollinger Band 26.97
Lower Bollinger Band 18.26
Percent B (%b) 0.48
BandWidth 38.52
MACD Line 0.97
MACD Signal Line 0.89
MACD Histogram 0.0772
Fundamentals Value
Market Cap 3.51 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -16.06
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.87
Resistance 3 (R3) 25.06 24.47 24.47
Resistance 2 (R2) 24.47 23.86 24.37 24.33
Resistance 1 (R1) 23.47 23.48 23.18 23.28 24.20
Pivot Point 22.88 22.88 22.73 22.78 22.88
Support 1 (S1) 21.88 22.27 21.59 21.69 20.76
Support 2 (S2) 21.29 21.89 21.19 20.63
Support 3 (S3) 20.29 21.29 20.49
Support 4 (S4) 20.10